Sanofi GCVRZ 深 滬
等待開盤 08-21 09:30:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多药物受理最新动态：Sanofi-Aventis Recherche & DéveloppementLunsekimig注射液补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月20日，Sanofi-Aventis Recherche & Développement的Lun...
08-20 17:15
药物受理最新动态：Sanofi Winthrop Industrie碳酸司维拉姆片进口再注册申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月19日，Sanofi Winthrop Industrie的碳酸司维拉姆片申请已获受理，受理号为JYHZ...
08-19 20:15
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Sanofi SA (NASDAQ:SNY) announced the withdrawal of its regulatory application in Europe for Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid. In June 2025, the U.S. Food and Drug Administration approved Dupixent, developed by Regeneron Pharmaceuticals Inc. (NASDAQ:REGN...
08-18 22:46
U.K. regulator reaffirms safety of childhood vaccination
Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it rema...
08-12 21:13
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals appoints John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed, currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, brings extensive experience in advancing innovative medicines and leading global R&D strategies. His expertise will support Madrigal's growth in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, particularly with its approved dr...
08-12 12:00
药物受理最新动态：Sanofi Winthrop Industrie尼塞韦单抗注射液进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月7日，Sanofi Winthrop Industrie的尼塞韦单抗注射液申请已获受理，受理号为JXSS...
08-07 14:15
Sanofi India posts robust Q2 2026 results, revamps board committees
An announcement from Sanofi India Limited ( ($IN:SANOFI) ) is now available. Sa...
08-04 23:16
Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease
Sanofi (SNY) received European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria mening...
08-04 17:12
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and Roche have initiated a global Phase 3 trial, DAYBreak CLL-306, to compare bexobrutideg, a BTK degrader, with pirtobrutinib in relapsed/refractory CLL/SLL patients who previously received covalent BTK inhibitors. The study aims to demonstrate bexobrutideg's superiority, with primary endpoints of ORR and PFS. This marks the first Phase 3 trial for bexobrutideg, targeting a new treatment approach for CLL.
08-04 05:00
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi SA (NASDAQ:SNY) on Thursday reported second-quarter sales of $13.482 billion (11.597 billion euros), beating the consensus of $12.65 billion. Sales increased 16% year over year, up 17.8% in constant currency. Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6...
07-31 02:45
